The efficacy of a health‐related quality‐of‐life intervention during 48 weeks of biologic treatment of patients with moderate to severe psoriasis: results of a multicentre randomized controlled trial

By  

BRITISH JOURNAL OF DERMATOLOGY, Vol. 173, Iss. 4, 2015-10 ,pp. : 1091-1094

John Wiley & Sons Inc

Access to resources Recommend Favorite

Adalimumab retreatment successfully restores clinical response and health‐related quality of life in patients with moderate to severe psoriasis who undergo therapy interruption

By  

JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY & VENEREOLOGY, Vol. 29, Iss. 4, 2015-04 ,pp. : 767-776

John Wiley & Sons Inc

Access to resources Recommend Favorite

Measuring health‐related quality of life in patients with mild to moderate eczema and psoriasis: clinical validity, reliability and sensitivity to change of the DLQI

By  

BRITISH JOURNAL OF DERMATOLOGY, Vol. 141, Iss. 4, 1999-10 ,pp. : 698-702

John Wiley & Sons Inc

Access to resources Recommend Favorite

Impact of ixekizumab on facial psoriasis and related quality of life measures in moderate‐to‐severe psoriasis patients: 12‐week results from two phase III trials

By  

JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY & VENEREOLOGY, Vol. 32, Iss. 1, 2018-01 ,pp. : 68-72

John Wiley & Sons Inc

Access to resources Recommend Favorite

Association between bleeding tendency and health‐related quality of life in carriers of moderate and severe haemophilia

By  

HAEMOPHILIA, Vol. 21, Iss. 6, 2015-11 ,pp. : 742-746

John Wiley & Sons Inc

Access to resources Recommend Favorite